RxDoctor Payments Data

Christine Wysocky

Family · Kingston, PANPI 1609484740

Payments from drug & device makers

$1,719in general payments, 2019–2025

Across 52 payments — averaging $33.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Braeburn Inc.$435
  • GSK$364
  • AbbVie$170
  • Amgen$146
  • Vanda Pharmaceuticals Inc.$137
  • Indivior Inc.$128
  • plus $340 from 8 others

What the payments were for

  • Food & beverage$1,719100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,719 in reported general payments places this provider in the 80th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$397
Medicare patients
12
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$16,281
XareltoRivaroxaban19$11,420
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,823
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$1,256
Albuterol Sulfate HfaAlbuterol Sulfate44$1,013
Atorvastatin Calcium57$406
Lisinopril48$289
Montelukast Sodium18$279
Gabapentin36$222
Metformin Hcl39$207
Metoprolol Succinate15$206
Potassium Chloride15$195
Pantoprazole Sodium13$190
Oxybutynin Chloride ErOxybutynin Chloride15$182
Hydrochlorothiazide42$176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$107$16,28116 claims
GSKTrelegy Ellipta$364$7,82312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,717 family providers in Pennsylvania.

Other family in Kingston

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →